Amplidyne, AMPD Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Amplidyne, AMPD

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: StockDung who wrote (147)	9/11/1999 2:51:00 PM
From: StockDung	of 538

Call Sharon Will, IR @ 212-572-0762. E-mail: sharon@saggicapit-al.com. [R-7; M-6; L-8] wallstreetcorner.com In 11/96, The Centers for Disease Control updated CFS to a Priority One Disease. It noted there were over 500,000 individuals in the U.S. infected with CFS, & about 500,000 in Europe. There is no other company in a Phase III trial for CFS. There have been over 20,000 weeks of treatment with Ampligen in patient therapies. Ampligen is the only drug given Treatment IND status & authorized by the FDA for use in a clinical trial with cost recovery for CFS. In 2/98 HEB signed a distri-bution/NDA agreement with Olsten Health Care. In 12/98 it submitted its NDA to regulatory authorities in the European Union. In 2/99 its marketing application in the European Union cleared the first stage of regulatory review by being designated as "complete" by the European Medical Evaluation Agency (EMEA). Call Sharon Will, IR @ 212-572-0762. E-mail: sharon@saggicapit-al.com. [R-7; M-6; L-8]

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next